The era of antidepressants
DOI:
https://doi.org/10.25118/2763-9037.2011.v1.920Keywords:
antidepressants, DepressionAbstract
Objective: To detect, through the analysis of the historical evolution of antidepressants (ADs) and their putative mechanisms of action, if there is a scientific basis that guides their clinical use. Method: analysis of relevant clinical studies and systematic reviews published over the last sixty years on the mechanisms of action and clinical use of ADs, their relationship with diagnostic classification systems in psychiatry, the role of regulatory agencies and the evolution of the system current patents. Results: it is not possible to justify with the available clinical-scientific data the clinical choice of this or that group of ADs. Conclusion: Open, double-blind, randomized clinical studies do not lend themselves to choosing the clinical use of a given AD. As “meta-analyses” are based on these studies, their results are conflicting. The choice of an AD continues to be based on the psychiatrist's experience.
Downloads
Metrics
References
. Thase ME. — Are SNRIs more effective than SSRIs? A review of the current state of the controversy — Psychopharmacol. Bull. 2008 41(2): 58-85.
. Rappaport,)). - The boy who could not stop washing — 1989 — E.P Dutton, N. York.
. Kendell, R.E; Cooper, ).E; Gourlay, AJ; Copelland, ).R;; Sharpe. & Gurland, B)). — Diagnostic criteria of American and British psychiatrisess — Arch.Gen.Psychiatry 1971 25: 1223-130.
. Kendell, RE. — Psychiatric diagnosis in Britain and the United States Br.). Psychiatry 1975 9: 453-461.
. Bueno, ).R. — Considerações e questionamentos sobre o “espectro bipolar” — Psychiatry on line — Brasil 2007 (outubro) vol. 13, nº 10.
. Kristnan, V. & Nestler, E). - The molecular neurobiology of depression — Nature 2008 455(16): 894-902.
. MccCall, WY. — Exploring the relationship between insomnia and depression — 2008 Psychiatry and Mental Health — Medscape 10/15/2008.
. Lopez-lbor, )). — Depressive Aquivalente. Das depressive Syndrom Int. Symposium 1968 - Urban & Schwarzenberg, Múnchen.
. Lopez-Ibor)). — Masked depression and depressive equivalents in Kielholz, P (Ed) - Depressive Illness — An International Symposium — 1972, pp 38-44 Hans Huber Publishers, Bern.
. Kielholz, P. (ed) - Masked Depression — An International Synposium — 1973, Hans Huber Publishers, Bern.
. Lesse, S. (ed) - Masked Depression — 1974, Jason Aronson, Inc. New York, 369 pp.
. Kielholz, P. (ed) Depressive Illness — An International Symposium — 1972, Hans Huber Publishers, Bern, 302 pp.
. Ayd, E). Jr. — Recognizing the Depressive Patient and Essentials of management and treatment — 1961, Grune & Stratton, N. York, 138 p.
. Shepherd, M. — Psychiatric illness in General Practice — 1966, Oxford University Press, London, 203 p.
. Pôldinger, W. — Kompendium der Psychopharmakotherapie — 1967, Hoffman La Roche A. G..
. Montgomery, S.A, & den Boer, ).A. — SSRIs in Depression and Anxiety — 2001, Perspectives in Psychiatry, vol 8, 2nd ed. — John Wiley & Sons Ltd, London, 234 p.
. Di Lampedusa, G.T. — Il Gattopardo — 1963, Universale Economica Feltrinelli Milano p 41.
. Jaspers, K. — Psychopthologie Générale — 1928, Librairie Félix Alcan, Paris — Traduit d'aprés la Troisiême Édition Allemande par A. KastleretJ . Mendousse.
. Schildkraut, )). — The cathecolamine hypothesis of effective disorders: a review of supporting evidence — 1965, Amer.). Pschiat. 122: 509- 516.
. Bunney, W.E, Jr. & Davis, J.M. — Norepinephrine in depressive reactions — 1965, Arch. Gen. Psychiat. 13: 483-490.
. Bunney, W.E, Jr; Murphy, D.L; Goodwin, FK. & Borge, G.F. — The switch process from depression to mania: relationship to drugs which alter brain amines — 1970, Lancet |: 1022-24.
. Ashcroft, GW. Crawford, T.B.B; Eccleston, D; Sharman, D.F; MacDougall, E); Stanton, ).B. & Binns, J.K. — 5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiarric or neurological diseases — 1966, Lancet ii: 1049-1055.
. Bourne, H.R; Bunney, W.E.Jr.; Colburn, RW. Davis, J.M.; Davis, ).N. Shaw, D.M. & Coppen, AJ. — Noradrenaline, 5-hydroxytriptamine and 5 hydroxyindoleacetic acid in hindbrain of suicidal patients — 1968, Lancet ii: 805-810.
. Coppen, AJ.; Shaw, D.M. & Farrell, ).P — Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan — 1963, Lancet i: 79-81.
. Coppen AJ; Shaw, D.M; Herzberg, B. & Maggs, R. — Tryptophan in the treatment of depression — 1967, Lancet il: 1178-80.
. Van Praag, H.M. — Antidepressants, catecholamines and 5-hydroxyindoles. Trends towards a more specific research in the field of antidepressants — 1967, Psychiat. Neurol, Neurochir. (Amst.) 70: 219-231.
. Bueno, ).R. & Himwich, H.E. — A dualistic approach to the biochemical problem in endogenous depression — 1967, Psychosomatics VII(2): 82-94.
. Coppen, AJ. Gupta, R; Montgomery, S.A; Ghosek,K,; Bailey, ); Burns, B, & Ridder, ).). - Mianserin hydrochloride: a novel anti-depressant - 1976, 129: 342-345.
. Healy, D. — Let them eat Prozac — The unhealthy relationship between the pharmaceutical industry and depression — 2004, New York University Press, New York, pp 4-60.
. Le Fur G, Kabouche, M. & Uzan, A. — On the regional and specific serotonin reuptake inhibition by LM 5008 — 1978, Life Sci. 23: 1959-1966.
. Montgomery, S.A; Rani, SJ; McAuley R. & Montgomery, D.B. — The antidepressant efficacy of zimelidine and maproptiline — 1981a, Acta Psychiat. Scand. 290(suppl): 21-24.
. Montgomery, S.A; McAuley, R; Rani, SJ; Roy, D. & Montgomery, D.B. — A double-blind comparison of zimelidine and amitryptiline in endogenous depression — 1981b, Acta Psychiat. Scand. 290 (suppl): 25-27.
. Naylor, G)). & Martin, B — A double-blind out-patient trial of indalpine vs.mianserin — 1985, Brit. ). Psychiat. 147:306-309.
. Gisselman, A. — Activity and acceptability of indalpine in a double-blind study versus placebo 1984, LEncephale 10(5): 231-234.
Lôo, H:; Brukelfar, C; Poirier. M.F; Vanelle, J-M; Olié, )-P; Dennis, T. & Scatton, B. — Plasma 3,4 dihydroxyphenylethyleneglycol and therapeutic response to maprotiline and indalpine in major depression — 1986, Neuropsychobiology 15: 62-67.
. Seletu,B, Schjerve M, Grúnberger, )., Schanda,H. & Arnold, O.H. —Fluvosamine — A new serotonin re-uptake inhibitor. First clinical and psychometric experience in depressed patients 1977, ). Neural Transmission 47: 17-36.
. Feldman, H.S. & Denber, H.C.B. — Long-term study of fluvoxamine: a new rapid-acting antidepressant 1982, Intl.Pharmacopsychiat. 17: 114-122.
. De Wilde, JEM. & Doogan, D.P. — Fluvoxamine and chloroimipramine in endogenous depression - 1982, ).Affect.Disord. 4: 244-259.
. De Wilde, ).E.M, Mertens, C. & Wakelin, ).S. Clinical trials of fluvoxamine vs.chloroimipramine with single and three times daily dosing 1983(supp), Brit). clin. Pharmac. 15: 427-431.
. Dick. P. & Ferrero, E. —- A double-blind comparative study of the clinical efficacy of fluvoxamine and chloroimipramine — 1983(supp) Brit). clin. Pharmac. 15: 419-425.
. Guelf, ).D. Dreyfus, ).F. & Pichot, P. — a double-blind controlled trial comparing fluvoxamine with imipramine 1983(supp) 15: 411-417.
. WilsonW.H. Higano, H., Papadatos, Y, Kelwala, S. & Ban, T.A. — A double-blind placebo controlled study to compare the autonomic effects of fluvoxamine with those of amitryptiline and doxepin in healthy volunteers 1983(supp), 15: 385-392.
. Siddiqui, V.A. Chakravarti, S.K. & Jessinger, D.K. — The tolerance and antidepressive activity of fuvoxamine as a single dose compared to a twice daily dosage — 1985 Curr.Med.Res. and Opinion 10(9): 681-691.
. Martin, AJ. Tebbs, V.M. & Ashford, )). — Affective disorder in general practice — Treatment of 6000 patients with fluvoxamine — 1987 — Pharmacotherapeutica 5(1): 40-49.
. Del Porto).A. Feijó de Mello, A. Ker-Correa, F, Santos Jr. A, Moreno, R.A, Rodrigues dos Santos, C.H, Chaves, AV, Versiani M, Nardi A.E, Oliveira, LR, Ribeiro,M.G, KapczinskiF, Gazalle, F, Frey, B. & Tamai, S. — Fluvoxamina no transtorno depressivo maior em estudo multicêntrico aberto — 2007 ).Bras.Psiquiatr. 56(1): 17-22.
. Montgomery, S.A; Bullock, T. & Pinder, RM. — The clinical profile of mianserin — 1997, Nordic ). Psychiat. 45(S24); 27-35.
. Danish University Antidepressant Group(DUAG) — Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study — 1986, Psychopharmacology 90: 131-138.
. DUAG — Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in controlled multicenter study — 1990, ).Affect. Disord. 18:289-299.
. Anderson, M. — SSRIs versus tricyclic antidepressants in depressed in-patients: a metanalysis of efficacy and tolerability — 1998, Depress. Anxiety 7: 11-17.
. Nemeroff, C.B.; Entsuah, A.R.; Benattin, |; Demitrack, M. Sloan, D.M. & Thase, M.E. — Comprehensive analysis Of remission (COMPARE) with venlafaxine versus SSRIs — 2008, Biol.Psychiat. 63: 424-434.
. Kavijaran, H. — Venlafaxine and SSRIs: remission data revised — 2004, Brit.).Psychiat. 184:452-453.
. Montgomery, S.A. & Anderson, H.F. — Escitalopram versus venlafaxine XR in the treatment of depression — 2006, Int.Clin.Psychopharmacol. 21: 297-309.
. Thase, M.E. — Recent developments in the pharmacotherapy of depression — 2000, Psychiat.Clin.North America Annaul Drug Therapy 7: 151171.
. Thase, M.E. — Managing depressive and anxiety disorders with escitalopram — 2006, Expert Opin.Pharmacotherapy 7: 429-440.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 João Romildo Bueno
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
